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To assess the efficacy of intravenous streptokinase in 
patients with acute myocardial infarction, 40 patients 
(30 men and 10 women, mean age 54 years) with acute 
myocardial infarction were given 1.5 million U of strep•
tokinase intravenously in 1 hour, and coronary arteri•
ography was performed repeatedly to assess reperfusion. 
Streptokinase treatment was begun 270 ± 86 (mean ± 
SD) minutes after the onset of chest pain. Of the 40 
patients, 34 had total or near total coronary occlusion 
before streptokinase administration. In 14 (41 %) of these 
34 patients, some reperfusion occurred during the 90 
minutes after the administration of streptokinase, but 
During the past several years, a number of studies have 
demonstrated that acute transmural myocardial infarction is 
frequently associated with coronary thrombosis (1) and that 
the prompt administration of a thrombolytic agent, such as 
streptokinase, may reestablish anterograde flow in the in•
volved coronary artery (2-5). Some studies have suggested 
that timely reperfusion may improve left ventricular function 
(3) and survival (4) over the several months after the acute 
event. Intracoronary streptokinase induces thrombolysis in 
70 to 80% of patients with acute myocardial infarction (2-5), 
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in only 11 of the 14 was reperfusion present at 90 rhin•
utes. After streptokinase administration, all patients re•
ceived heparin for 8 to 10 days; they were subsequently 
administered aspirin and dipyridamole. Clinical evi•
dence of reocclusion during the first 24 hours of heparin 
therapy occurred in one patient. Thus, when given to 
patients with acute myocardial infarction and total coro•
nary occlusion an average of 41/2 hours after the onset 
of chest pain, high dose intravenous streptokinase achieves 
reperfusion in only about 40 % and results in sustained 
reperfusion in only about 30%. 
(J Am Coil CardioI1985;6.·957-62) 
but its widespread application in such patients is limited, 
because it requires the immediate availability of a cardiac 
catheterization laboratory and appropriate personnel. Intra•
venous streptokinase can be administered quickly and does 
not require sophisticated and expensive invasive facilities. 
Several studies have shown that it is generally safe and well 
tolerated, but results concerning therapeutic efficacy have 
been widely disparate. Rogers et al. (6) and Spann et al. 
(7,8) showed that intravenous streptokinase causes throm•
bolysis in less than 50% of patients, whereas Ganz et al. 
(9) reported lysis in 96% of patients. 
In 1983, the National Heart, Lung, and Blood Institute 
initiated a collaborative clinical trial of intravenous throm•
bolytic therapy in patients with acute myocardial infarction. 
For this multicenter effort, 13 clinical centers, 5 core lab•
oratories, a drug distribution center and a data coordinating 
center were organized to plan and perform the Thrombolysis 
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in Myocardial Infarction (TIMI) Trial. The planning com•
mittee determined that the first phase (phase I) should com•
pare the efficacy and safety of intravenous streptokinase and 
intravenous tissue-type plasminogen activator in a double•
blind, randomized fashion. As a prelude to phase I, strep•
tokinase was administered in open label fashion to 40 pa•
tients. This phase of our study is described in this report. 
Methods 
Patient population. At the 13 clinical centers, patients 
were enrolled in the study and given intravenous strepto•
kinase if they met the following criteria: 1) younger than 
76 years of age; 2) chest pain compatible with acute myo•
cardial infarction greater than 30 !Tlinutes in duration; 3) 
electrocardiographic ST segment elevation of 0.1 mV or 
greater in 2 or more of the standard 12 leads; 4) an elapsed 
time from onset of chest pain to enrollment of less than 7 
hours; and 5) coronary arteriographic evidence of 50% or 
greater luminal diameter narrowing of the artery supplying 
the area of infarction. Patients were excluded from enroll•
ment if they had any of the following: 1) severe hypotension 
(systolic arterial pressure < 80 mm Hg) despite vasopres•
sors; 2) llncontrolled hypertension (diastolic pressure> 120 
mm Hg); 3) child-bearing potential; 4) a history of a bleeding 
disorder or an illness that placed the patient at high risk of 
a hemorrhagic complication with thrombolytic therapy, for 
example, previous gastrointestinal bleeding, an underlying 
malignancy, surgery in the preceding 2 weeks, a severe 
traumatic injury in the preceding 6 months or a cerebro•
vascular accident in the preceding 6 months; 5) the presence 
of known dilated cardiomyopathy, left bundle branch block 
or previous coronary artery bypass surgery; 6) previous par•
ticipation in the TIMI Trial; and 7) inability to give informed 
consent. 
Study design. After informed consent was obtained, each 
patient was taken immediately to the cardiac catheterization 
laboratory, and venous and arterial access were obtained. 
The coronary artery believed (from the electrocardiogram) 
not to be involved in the infarction was injected selectively, 
after which the "infarct-related artery" was visualized in a 
series of standard views. If the infarct-related artery had 
50% or greater luminal diameter narrowing, intracoronary 
nitroglycerin (200 JLg) was given, and arteriography was 
repeated. If the artery remained narrowed by 50% or greater, 
the patient received intravenous streptokinase, 1.5 million 
U during 1 hour. Cineangiography of the involved coronary 
artery was performed 10, 20, 30, 45, 60, 75 and 90 minutes 
after the initiation of streptokinase. 
At the end of the streptokinase infusion, intravenous hep•
arin therapy was begun at 1,000 U/h. After the 90 minute 
cine angiogram , the patient was transferred to the coronary 
care unit with venous and arterial sheaths in place. Heparin 
treatment was continued for 8 to 10 days, during which time 
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an attempt was made to maintain the activated partial throm•
boplastin time at 2 to 2112 times normal. The vascular sheaths 
were removed 24 to 48 hours after streptokinase adminis•
tration. After 8 to 10 days of heparin therapy, aspirin and 
dipyridamole were administered and heparin was discontin•
ued. If possible, a repeat cardiac catheterization, including 
selective coronary arteriography, was performed at this time. 
Measurements. A Coagulation Core Laboratory was es•
tablished at the Thrombosis Research Center, Temple Uni•
versity, Philadelphia, Pennsylvania, to assess the changes 
in plasma levels of fibrinogen, plasminogen and fibrinogen 
degradation products. Blood samples were collected before 
and I to 3 and 24 hours after the initiation of streptokinase. 
In addition, samples were obtained at the time of hospital 
discharge (8 to 10 days later). Because of the presence of 
heparin in the blood samples, fibrinogen concentrations were 
measured by the method of Martinek and Berry (10) in 
citrated plasma prepared from blood collected in the pres•
ence of 250 U/ml of aprotinin (Trasylol, FBA Pharmaceu•
ticals). Plasma plasminogen activity was measured in ci•
trated plasma by the method of Friberger and Knos (11) 
using a chromogenic substrate, S-2251 (Kabi Diagnostics). 
The results are expressed as percent of activity in relation 
to that in pooled normal plasma taken as 100%. The levels 
of fibrinogen degradation products were measured in serum 
harvested from blood (2 ml) collected in tubes containing 
thrombin (20 NIH U), soybean trypsin inhibitor (3,670 NF 
U) and protamine sulfate (50 JLg, Eli Lilly Company). The 
Thrombo-Wellcotest method was employed using latex par•
ticles coated with antibodies against fibrinogen fragments 
D and E (WelIcome Diagnostics). 
Analysis of data. The cineangiograms obtained during 
both catheterizations were analyzed by the Radiographic 
Core Laboratory at the University of Washington, Seattle, 
Washington. In assessing the adequacy of perfusion in the 
infarct-related artery, the following grading system was used: 
grade 0 = no anterograde movement of contrast material 
beyond the point of occlusion ("no perfusion "); grade 1 = 
penetration of the obstruction with contrast material but 
failure to opacify the distal coronary artery bed (' 'minimal 
perfusion"); grade 2 = passage of contrast material past 
the obstruction, with anterograde movement and clearance 
of contrast material slower than that seen in a nondiseased 
artery ("partial perfusion"); and grade 3 = prompt ap•
pearance and disappearance of contrast material in the por•
tion of the artery distal to the obstruction ("complete per•
fusion"). On the basis of this grading system, coronary 
occlusion was considered to be present when perfusion was 
graded as 0 or 1, and reperfusion was believed to have 
occurred if perfusion improved to grades 2 or 3. 
Clinical evidence of reocclusion after streptokinase 
administration was believed to be present if at least two of 
the following occurred: I) reappearance or distinct wors•
ening of ischemic pain similar in nature to the pain of in-
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farction; 2) 0.1 m V or greater ST segment elevation or 
reelevation in the electrocardiographic leads in which it was 
present on the qualifying electrocardiogram; and 3) a greater 
than 50% increase in serum creatine kinase in two consec•
utive samples, each containing the MB isoenzyme. 
In assessing the plasminogen, fibrinogen and fibrinogen 
degradation product concentrations before streptokinase in•
fusion and I to 3 and 24 hours and 8 to 10 days after 
streptokinase initiation, a paired t test was used. All data 
are reported as mean ± SD. For all analyses, a probability 
(p) value of less than 0.05 was considered significant (12,13). 
Results 
Patient features. Forty patients (30 men and 10 women, 
aged 54 ± II years; range 38 to 75) with acute myocardial 
infarction received intravenous streptokinase. Initial 12 lead 
electrocardiography revealed ST segment elevation in the 
anterior leads in 18 patients, the inferior leads in 18 and 
both the anterior and the inferior leads in 4. By cineangi•
ography, the right coronary artery was the involved vessel 
in 21, whereas the left anterior descending coronary artery 
was involved in 19. Of the 40 patients, 19 had single vessel 
coronary artery disease, 13 had double vessel disease and 
8 had triple vessel disease. The elapsed time from the onset 
of chest pain to the institution of thrombolytic therapy av•
eraged 270 ± 86 minutes (range 137 to 482); it was less 
than 240 minutes in 16 patients. 
Cineangiographic and clinical results. Before strep•
tokinase administration, 6 patients showed angiographic 
evidence of partial occlusion (perfusion grades 2 or 3), 
whereas in the other 34 the infarct-related vessel was totally 
or nearly totally occluded (perfusion grades 0 or I). During 
the 90 minutes after the initiation of intravenous strepto•
kinase, reperfusion (an improvement to perfusion grades 2 
or 3) occurred in 14 (41 %) of these 34 patients (Fig. 1). 
Furthermore, 90 minutes after streptokinase was begun, 3 
of the 14 once again showed total occlusion. Five patients 
demonstrated only partial reperfusion (grade 2) and the other 
six continued to have total reperfusion (grade 3). Of the five 
patients with partial reperfusion 90 minutes after the insti•
tution of streptokinase, four had no clinical evidence of 
reocclusion during the subsequent 24 hours, and one had 
prolonged chest pain 3 hours after the termination of strep•
tokinase therapy (at a time when the activated partial throm•
boplastin time was 102 seconds [control value 35]). Of the 
six patients with complete reperfusion 90 minutes after the 
institution of streptokinase, none had clinical evidence of 
reocclusion during the next 24 hours. 
Thus, of the 34 patients whose infarct-related artery was 
occluded before streptokinase therapy, only 10 (29%) dem•
onstrated successful reperfusion 90 minutes after the insti•
tution of streptokinase and no clinical evidence of reocclu•
sion during the next 24 hours (Fig. 1). 
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Figure 1. Schematic outline of the angiographic results in the 40 
patients receiving intravenous streptokinase. As noted, of the 34 
with total occlusion before streptokinase administration, only 14 
(41%) had some reperfusion during the subsequent 90 minutes. 
Twenty-four hours after drug administration, only 10 (29%) had 
achieved reperfusion at 90 minutes and had no clinical evidence 
of reoccJusion. 
Of the 16 patients who received streptokinase earlier than 
4 hours after the onset of chest pain, 15 had perfusion grade 
o or 1 of the infarct-related artery before drug administra•
tion. In 5 (33%) of these 15, partial or complete reperfusion 
(grade 2 or 3) was noted at 90 minutes. Of the 24 subjects 
who received streptokinase more than 4 hours after the onset 
of pain, 19 had perfusion grade 0 or 1 of the infarct-related 
artery before the institution of therapy. In 6 (32%) of these 
19, partial or complete reperfusion (grade 2 or 3) was ob•
served at 90 minutes (P = NS in comparison with the 
patients who received streptokinase <4 hours after the onset 
of pain). 
Repeat catheterization was performed 8 to 10 days after 
streptokinase administration in 22 patients. Eighteen did 
not have repeat catheterization because of patient refusal 
(n = 8), referring physician refusal (n = 2), death (n = 
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2) or the necessity for coronary artery bypass surgery or 
angioplasty during the several days after streptokinase ther•
apy (n = 6). Repeat catheterization was performed in 6 of 
the 11 patients with complete or partial reperfusion at 90 
minutes; persistent patency was demonstrated in 5 and to•
tally occluded vessel in 1 patient. Repeat catheterization 
was accomplished in 13 of the 23 patients who had grade 
o or 1 perfusion at 90 minutes. Although six still had grade 
o or 1, the other seven had grade 2 or 3. In these seven, 
anterograde flow was reestablished at some time between 
the 90 minute cineangiogram and the repeat study. 
As noted, streptokinase induced reperfusion during the 
90 minutes of observation in 14 patients. In three of these 
patients, however, the infarct-related artery was occluded 
once again 90 minutes after streptokinase treatment was 
begun. A repeat catheterization 8 to 10 days after strepto•
kinase administration was performed in only one of these 
three subjects; in this individual, the infarct-related artery 
was totally reperfused (grade 3). 
Coagulation results. Mean values for plasminogen, fi•
brinogen and fibrinogen degradation products are displayed 
in Table 1. With the administration of streptokinase, plas•
minogen and fibrinogen levels decreased and fibrinogen deg•
radation products increased. These findings are consistent 
with the induction of a systemic lytic state by streptokinase. 
At the time of hospital discharge 8 to 10 days later, plas•
minogen and fibrinogen degradation product concentrations 
were similar to baseline study, whereas fibrinogen levels 
were significantly higher than baseline study. 
Morbidity and mortality during streptokinase ther•
apy. Of the 40 patients receiving intravenous streptokinase, 
3 (8%) died during the month after the institution of therapy; 
in all 3, death was attributed to severe underlying coronary 
artery disease and its sequelae. Almost all morbidity was 
due to bleeding and, in most patients, did not interfere with 
the ability of the investigators to adhere to the protocol. The 
appearance of a hematoma at the site of venous and arterial 
punctures was noted in 26 patients. Six subjects had a suf•
ficient decrease in hematocrit to require transfusion. Gas•
trointestinal bleeding occurred in two patients, but surgical 
intervention was not required. Although hemorrhagic events 
were frequent, none were fatal. 
Table 1. Coagulation Results 
Before 
Variable Streptokinase 
Plasminogen (%)(n = 29)t 97 :t 22 
Fibrinogen (mg/dl)(n = 30) 342 ± 98 
Fibrinogen degradation products 21 ± 80 
(/-tg/ml)(n = 30) 
Discussion 
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In patients with acute transmural myocardial infarction, 
intracoronary streptokinase has been shown to induce 
thrombolysis rapidly in 70 to 80% (2-5). However, its ap•
plication to large numbers of patients is limited, because a 
cardiac catheterization laboratory and supporting technical 
personnel are required. Intravenous streptokinase can be 
given quickly without the need for a catheterization labo•
ratory. Several investigators (6-8,14-16) administered high 
dose (500,000 to 1,500,000 U over 15 to 90 minutes) in•
travenous streptokinase and performed acute coronary an•
giography to assess its efficacy in causing reperfusion. In 
general, thrombolysis was achieved in about half the pa•
tients, ranging from 44 (6) to 63% (14). In other studies in 
which the occurrence of thrombolysis was judged by indirect 
criteria (without acute angiography), intravenous strepto•
kinase was reported to induce thrombolysis in 96% (9). 
In the present study, intravenous streptokinase, 1.5 mil•
lion U given over 1 hour, induced acute reperfusion in only 
41 % of patients, and persistent reperfusion without clinical 
evidence of reocclusion was present in only 29% (Fig. 1). 
In our experience, therefore, high dose intravenous strep•
tokinase successfully induces thrombolysis and sustains ves•
sel patency in only a few patients. 
Possible reasons for the low reperfusion rate in this 
study. In all studies that demonstrated angiographicaUy that 
intravenous streptokinase achieves thrombolysis in more than 
50% of patients, the drug was administered an average of 
less than 4 hours from the onset of chest pain. Neuhaus et 
al. (14) gave intravenous streptokinase an average of 3.2 
hours after chest pain and achieved thrombolysis in 24 (63%) 
of 38 patients; Schroder et al. (15) administered the drug 
an average of 3.8 hours after the onset of chest pain, and 
thrombolysis occurred in 11 (52%) of 21 patients; Alderman 
et al. (16) gave streptokinase an average of 203 minutes 
after the appearance of chest pain, achieving lysis in 8 (62%) 
of 13 patients. In contrast, Rogers et al. (6) gave high dose 
intravenous streptokinase an average of 6 to 7 hours after 
the onset of chest pain, and lysis occurred in only 7 (44%) 
of 16 patients. A similar reperfusion rate (21 [49%] of 43) 
was noted by Spann et al. (8) when streptokinase was given 
I to 3 Hours 
After 
Streptokinase 
15 :t 8* 
161 ± 85* 
283 ± 168* 
24 Hours 
After 
Streptokinase 
37 :t 12' 
239 ± 92* 
70 ± 41* 
At Hospital 
Discharge 
107 :t 35 
638 ± 280* 
I ± 4 
All data are mean ± standard deviation. *p < 0.01 in comparison with baseline study (before streptokinase 
administration); tplasminogen results are expressed as percent of activity of pooled normal plasma taken as 
100%. 
lACC Vol. 6. No.5 
November 1985:957-62 
within 6 hours of chest pain. In our study, intravenous 
streptokinase was given an average of 270 ± 86 minutes 
after the onset of pain and within 4 hours in only 16 patients. 
Similar to the studies just mentioned (6,8,14-16), the 
administration of streptokinase was delayed in each patient 
until coronary arteriography was accomplished so that re•
perfusion could be evaluated directly. The acute reperfusion 
rate among patients with coronary occlusion was 41 %, a 
result similar to that of Rogers et al. (6) and Spann et al. 
(8), whose average elapsed time from chest pain to insti•
tution of streptokinase was similar to ours. Thus, as noted 
by others (14,15), the likelihood that intravenous strepto•
kinase will induce thrombolysis appears to be related to the 
elapsed time from the chest pain, which may be presumed 
to be the time of thrombus formation. 
In our study, coronary arteriography was performed re•
peatedly for 90 minutes after the administration of intra•
venous streptokinase. During this period of arteriographic 
observation, reperfusion occurred in 14 (41 %) of 34 patients 
but was not noted in the other 20 (59%). In some of these 
20 patients, it is conceivable that thrombolysis with resultant 
reperfusion occurred after the 90 minute arteriogram. 
Successful maintenance of reperfusion after strepto•
kinase therapy. In the present study, acute reperfusion 
occurred in 14 (41 %) of 34 patients but was sustained in 
only IO (29%) (Fig. I). Spann et al. (8) noted a similar 
finding: of 43 patients given intravenous streptokinase, early 
reperfusion occurred in 21 (49%) but was sustained in only 
15 (35%). As suggested by Harrison et al. (17), the patients 
in whom reperfusion occurred but was not sustained may 
have had residual high grade coronary artery stenosis with 
an extremely small cross-sectional area, rendering them at 
high risk of rethrombosis during the hours to days after 
thrombolytic therapy. 
Conclusions. Our data, obtained in a consecutive cohort 
of patients with acute myocardial infarction from a number 
of centers throughout the country, demonstrate that high 
dose intravenous streptokinase achieves thrombolysis in only 
about 40% of patients and leads to persistent vessel patency 
in only about 30%. If intravenous thrombolytic therapy is 
to have a substantial impact on the morbidity and mortality 
of acute myocardial infarction, an agent that achieves throm•
bolysis in a higher percentage of patients must be identified, 
tested and proved effective and safe. 
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MD, Suzanne Wingate, RN. 
Harvard University, Boston, MA. Principal Investigator: John E. Mar•
kis, MD; Co-Investigators: James Alderman, MD, Cynthia Brewer, RN, 
Raymond G. McKay, MD. 
Mayo Foundation, Rochester, MN. Principal Investigator: James H. 
Chesebro, MD; Co-Investigators: Dennis R. Bresnahan, MD, Bernard J. 
Gersh, MD, LaVon Hammes, RN, Laurie Meyers, LPN, Fletcher A. 
Miller, MD, Michael B. Mock, MD, Hugh C. Smith, MD. 
University of Massachusetts, Worcester, MA. Principal Investigator: 
James E. Dalen, MD; Co-Investigators: Joseph S. Alpert, MD, Steven P. 
Ball, RN, Joseph R. Benotti, MD, Paul Doherty, MD, Joel M. Gore, MD, 
Ira S. Ockene, MD, James F. Rippe, MD, Bonnie H. Weiner, MD. 
University of Texas, Dallas, TX. Principal Investigator: James Will•
erson, MD; Co-Investigators: L. David Hillis, MD, George Revtyak, MD, 
Blair Toates, RN, Michael Winniford, MD. 
Washington University, St. Louis, MO. Principal Investigator: Philip 
A. Ludbrook, MD; Co-Investigators: Allan S. Jaffe, MD, Peter B. Kurnik, 
MD, Nancy A. Ricciotti, RN, MSN, Burton E. Sobel, MD, James J. 
Spadaro, MD, Allan J. Tiefenbrunn, MD. 
Yale University, New Haven, CT. Principal Investigator: Charles K. 
Francis, MD; Co-Investigators: Henry S. Cabin, MD, Lawrence S. Cohen, 
MD, Caroline Piselli, RN, Daniel Wohlgelernter, MD. 
Coordinating Center 
Maryland Medical Research Institute, Inc., Baltimore, MD. Prin•
cipal Investigator: Genell L. Knatterud, PhD; Co-Investigators: Paul L. 
Canner, PhD, Sandra Forman, MD, Dorothy T. Harris, William F. Krol, 
PhD, Michael L. Terrin, MD, MPH, Patricia C. Wilkins, BS. 
Radiographic Core Laboratory 
University of Washington, Seattle, WA. Principal Investigator: Harold 
T. Dodge, MD; Co-Investigators: Rodney S. Badger, MD, B. Greg Brown, 
MD, J. Ward Kennedy, MD, Florence H. Sheehan, MD. 
Radionuclide Core Laboratory 
Yale University, New Haven, CT. Principal Investigator: Barry Zaret, 
MD; Co-Investigator: Frans Wackers, MD. 
Coagulation Core Laboratory 
Temple University, Philadelphia, PA, Principal Investigator: A. Ko•
neti Rao, MD; Co-Investigators: Robert W. Coleman, MD, Andrei Z. 
Budzynski, PhD. 
Pathology Core Laboratory 
National Institutes of Health Clinical Center, Bethesda, MD. Prin•
cipal Investigator: William C. Roberts, MD; Co-Investigator: Deborah 
Barbour, MD. 
National Heart, Lung, and Blood Institute Program Office 
National Institutes of Health, Bethesda, MD, Principal Investigator: 
Eugene R. Passamani, MD; Co-Investigators: Kent R. Baily, PhD, Patrice 
M. Desvigne-Nickens, MD, Thomas L. Robertson, MD, Janet T. Wittes, 
PhD. 
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